Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Damien Prouzeau, Ismaël Conejero, Peter L. Voyvodic, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 10, pp. 573-581
Closed Access | Times Cited: 20

Showing 20 citing articles:

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
Guy M. Goodwin, Megan Croal, David Feifel, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 10, pp. 1492-1499
Open Access | Times Cited: 89
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 26
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
Mehdi Sekssaoui, Joël Bockaert, Philippe Marin, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 4, pp. 747-756
Open Access | Times Cited: 25
Emerging Challenges for Psychedelic Therapy
Jacob S. Aday, Robin Carhart‐Harris, Joshua D. Woolley
JAMA Psychiatry (2023) Vol. 80, Iss. 6, pp. 533-533
Closed Access | Times Cited: 34
Methyl transfer in psilocybin biosynthesis
Jesse Hudspeth, Kai Rogge, Sebastian Dörner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice
Youge Qu, Lijia Chang, Li Ma, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 222, pp. 173500-173500
Closed Access | Times Cited: 32
Prophylactic effects of arketamine, but not hallucinogenic psychedelic DOI nor non-hallucinogenic psychedelic analog lisuride, in lipopolysaccharide-treated mice and mice exposed to chronic restrain stress
Guilin Liu, Li Ma, Youge Qu, et al.
Pharmacology Biochemistry and Behavior (2023) Vol. 233, pp. 173659-173659
Closed Access | Times Cited: 12
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
I. Erkizia-Santamaría, Igor Horrillo, J. Javier Meana, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111249-111249
Closed Access
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders (2024) Vol. 372, pp. 523-532
Closed Access | Times Cited: 3
Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity
Jennifer Warner‐Schmidt, Christopher Pittenger, Martin Stogniew, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 7
Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats
Elizabeth L. Fisher, Ryan Smith, Andrew W. Corcoran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats
Elizabeth L. Fisher, Ryan Smith, Kyna‐Anne Conn, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Substrate recognition by the 4‐hydroxytryptamine kinase PsiK in psilocybin biosynthesis
Kai Rogge, Tobias Wagner, Dirk Hoffmeister, et al.
FEBS Letters (2024)
Open Access | Times Cited: 1
The zebrafish for preclinical psilocybin research
Omer A. Syed, Benjamin Tsang, Robert Gerlai
Neuroscience & Biobehavioral Reviews (2023) Vol. 153, pp. 105381-105381
Closed Access | Times Cited: 3
Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge
Marcha Verheijen
Deleted Journal (2024) Vol. 1, Iss. 1
Open Access
The role of psilocybin in depressive disorders
Jadwiga Najib
Current Medical Research and Opinion (2024) Vol. 40, Iss. 10, pp. 1793-1808
Closed Access
Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design
Elena Koning, Cristiano Chaves, Ryan H. Kirkpatrick, et al.
Journal of Eating Disorders (2024) Vol. 12, Iss. 1
Open Access
Can a single dose of psilocybin improve cognitive control in functional dissociative seizures?
Julien Chupin, Jorge López‐Castromán, Caroline Brière, et al.
Medical Hypotheses (2023) Vol. 179, pp. 111163-111163
Open Access
Neuropsychological Effects of Antidepressants: Translational Studies
Katie Kamenish, Emma Robinson
Current topics in behavioral neurosciences (2023), pp. 101-130
Closed Access
Application of psilocybin in mental health disorders
Jingxuan Chen
Theoretical and Natural Science (2023) Vol. 21, Iss. 1, pp. 173-179
Open Access
Page 1

Scroll to top